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Book Reviews
Carl F. Cranor, Regulating Toxic Substances (Oxford University Press
1993). Acknowledgments, appendices, bibliography, figures, foreword by The
Honorable George E. Brown, Jr., index, notes, tables. LC 91-47046; ISBN 0-19-
507436-X. [272 pp. Cloth $45.00. 200 Madison Avenue, New York NY 10016.]
The recent Supreme Court decision, Daubert v. Merrell Dow
Pharmaceuticals, Inc. 1 answered one question regarding court use of
scientific evidence. It held that trial judges are to fulfill a gatekeeper
role, admitting for consideration by the fact-finder only evidence that
they find to be both relevant and reliable. Thus, the judge must assess
the principles and methodology underlying the proffered evidence, and
not the conclusions drawn therefrom. 2 A more difficult question that
1 113 S.Ct. 2786 (1993). The opinion is starting to influence lower courts, but it is
unknown what the ramifications of Daubert will be. Compare Datskow v. Teledyne
Continental Motors Aircraft Pdts., 826 F. Supp. 677 (W.D. N.Y. 1993) (cites
Daubert but does not apply criteria) and Concerned Area Residents for the
Environment v. Southview Farm, 1993 U.S. Dist. LEXIS 14835 (W.D. N.Y. Oct. 19,
1993) (cites Daubert for proposition that weight of evidence is for jury) with In re
Joint Eastern and Southern District Asbestos Litigation, 827 F. Supp. 1014 (S.D. N.Y.
1993) (does not exclude evidence, but upsets jury verdict for lack of support) and
Chikovsky v. Ortho Pharmaceutical Corp., 1993 U.S. Dist. LEXIS 13342 (S.D. FL,
Sept. 22 1993) (excludes testimony of causal link between topical Retin-A and birth
defects). Arguably, Daubert gives litigants an additional tool to challenge proffers of
scientific evidence, which may lead to more challenges and a greater load on judges to
address the issues which many of them feel they are ill pre ared to manage. The early
disposition of these issues may lead to more rapid abandTonment and settlement of
cases, which may lead to greater efficiency in the system.
2 Daubert definitely requires greater judicial scrutiny of the empirical basis
underlying a witness' testimony, which may reduce the incidence of "junk science" in
the courts. See Peter W. Huber, Galileo's Revenge: Junk Science in the Courtroom
(1991); see also, Phantom Risk: Scientific Inference and the Law (Kenneth R. Foster,
David E. Bernstein & Peter W. Huber eds. 1993).
In the more recent book, the editors pull together chapters describing the state of
scientific knowledge in each of the following areas: electromagnetic fields and video
display terminals, spermicides, Bendectin, asbestos, environmental pollutants
(including dioxin, polychlorinated biphenyls, trichloroethylene, and radionuclides),
trauma-induced cancer, and clinical ecology. For each substantive area, a legal critique
of how the issues have fared in court is presented. Each subject is one in which
litigation has occurred under circumstances where the science tending to establish or
disprove a causal connection is (or was) uncertain. The editors draw on these examples
to criticize the judicial fact-finding process for its deviation from the fact-finding
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the Court did not reach is whether the standard of proof of science is
relevant in judicial fact-finding. This issue is explored in detail by
Cranor in his book.3
Cranor focuses on the different burdens of proof required in science
versus those required in courts of law. Perhaps for simplicity, science
and regulatory science (i.e., risk assessment) are treated as one. By co-
mingling science, risk assessment and risk management concepts, he
effectively undermines the reader's trust in the ability of science to
protect us from unknown hazards because of the limitations of risk
assessment. Cranor's arguments center on several major areas: (1) while
science endeavors to minimize false positives (e.g., concluding a
substance is carcinogenic when it in fact is not), science has been less
concerned with minimizing false negatives (e.g., finding that a
substance is not a concern when it in fact should be); (2) the slowness
of risk assessments and rule-making tend to favor the status quo and
may protect harmful chemicals better than public health; (3) science is
not concerned with distributional justice issues; and (4) tort law serves
as an important backup to administrative law in compensating victims
and deterring the marketing of harmful products.
Cranor calls for greater attention to minimizing false negatives. He
repeatedly states that the costs of under-regulation may be greater than
those of over-regulation, but little empirical evidence is offered to
support this assertion. As an additional justification for avoiding false
negatives, he relies on philosophical considerations of distributional
justice, in effect arguing for a. rights-based approach to protecting
individual health. More fundamentally, Cranor apparently attributes
false negatives to science, rather than to risk management. Technically,
as he acknowledges, science will not claim "negative" results, but only
reveal no effect above a certain detection limit.
processes of science. The assessment of the quality of scientific reasoning and
methodology obviously presents a challenge to the judiciary. See also, generally, The
Carnegie Commission on Science, Technology and Government, Science and
Technology in Judicial Decision Making: Creating Opportunities and Meeting
Challenges (1993).
3 In doing so, Cranor generally criticizes commentary calling for judicial restraint
in admitting scientific testimony. See, e.g., Regulating Toxic Substances, at 66.
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With regard to risk assessment and regulation, we agree
wholeheartedly with Cranor's recommendation that regulatory
scientists carefully display the limitations of their data, models and
conclusions. Scientists can provide a statement of knowledge of risks in
timely manner and with caveats as to uncertainty ranges, assumptions
and detection limits. Risk managers can then do the difficult job of
balancing this information with other factors. The explicit
characterization of uncertainty in data and models provides insights not
only into the limitations of scientific evidence but also into setting
research priorities which will bolster future risk management.
Cranor argues strenuously for the use of expedited approximation
procedures for conducting risk assessments. 4 He also suggests that
uncertainties may be "reduced" through risk management decisions. 5
In our view, uncertainty can be reduced only by developing better data
and models. A wide range of uncertainty opens the door for other
considerations (e.g., risk avoidance to protect public health, comparison
to other risks, and economic, social and political effects) to have key
roles in risk management. Such considerations should not enter into
regulatory science itself, such as through the use of compound
conservative assumptions.
Cranor asserts that the evidentiary standards of science should not
apply to risk assessment for regulatory purposes, arguing instead for use
of a "preponderance of evidence" standard of proof as applied in civil
litigation. Nonetheless, even though he argues for consistency in risk
assessment procedures, he appears less concerned with consistency of
the standards of evidence employed therein. As Cranor recognizes, it is
not clear how the choice of standards, on a necessarily ad hoc, case-by-
case basis, should be guided.
We view Cranor's approach to be highly risk averse, and the full
effect of his proposal on economic behavior is unknown. As a blanket
rule for risk regulation, we fear his approach would lead to less
4 See, e.g., id. at 137.
5 See, e.g., id. at 136.
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predictable regulations. 6 He exacerbates this problem by calling for
"universal" use of his proposed less comprehensive risk assessments,
which could lead to false categorization of regulated products and,
perhaps more dangerously, false reliance thereon.
Finally, with regard to civil litigation, Cranor's thesis has a certain
appeal: Actors who introduce risky goods into the market should do so
at their own economic peril: they should bear the burden of analyzing
their products and activities and ensuring that they are not too
hazardous. To illustrate his arguments, Cranor relies heavily on one
case, Ferebee v. Chevron Chemical Co.7 The Ferebee court
distinguished the scientific uses of evidence from the uses of such
evidence in the courts. Ferebee itself does not express a majority rule,
and judicial events in the last two years have further undermined the
precedential value of the case. 8 Nonetheless, from Cranor's discussion
of this case and the role of the courts in regulating risky behavior, we
6 This problem may also be exacerbated by publication bias, or the tendency on the
part of editors and authors to only publish positive results. This may lead to a biased
sampling system under which only those studies that suggest toxic qualities of
chemicals will initially make it into the literature. Since there is no good way to
identify negative results, especially before any suggestion of toxic qualities are raised,
then one suggestive study (even if statistically significant) may be quite inadequate,
under any burden of proof, to establish the hazardous nature of a chemical. See,
generally, Colin B. Begg & Jesse A. Berlin, Publication Bias: A Problem in
Interpreting Medical Data, 151 J. Royal Statist. Soc. 419 (1988); Robert Rosenthal,
The "File Drawer Problem" and Tolerance for Null Results, 86 Psychol. Bull. 638
(1979).
7 736 F.2d 1529 (D.C. Cir. 1984).
8 It is possible that the proffer of causation evidence in Ferebee would have been
inadmissible under Daubert. Further, the liability basis of Ferebee has been
substantially overturned by a line of cases following Cipollone v. Liggett Group, 112
S.Ct. 2608 (1992) and holding that various federal statutes preempt state failure-to-
warn doctrine. See Arkansas-Platte & Gulf Partnership v. Van Waters & Rogers Inc.,
981 F.2d 1177 (10th Cir. 1993) (pesticide); Shaw v. Dow Brands Inc., 61 U.S.L.W.
2727 (7th Cir. No. 92-2323, 1993) (bathroom cleaning products); Moss v. Parks
Corp., 985 F.2d 736 (4th Cir. 1993) (paint thinner); Papas v. Upjohn Co., 985 F.2d
516 (4th Cir. 1993) (pesticides); King v. E.I. DuPont de Nemours and Co., 996 F.2d
1346 (1st Cir. 1993) (herbicide).
Even in the D.C. Circuit, Ferebee has been limited to instances where the
evidence "stands at the frontier of current medical and epidemiological inquiry" and
thus not applied in cases where substantial scientific study, although inadequate to
prove (or disprove) a particular risk, is extant. In re Joint Eastern and Southern District
Asbestos Litigation, supra note 1.
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came away with the distinct impression that he views the imposition of
risk on any member of society as immoral.
Our system of tort law is not a system of absolute nor even "true"
strict liability. The law requires a balancing of risks and benefits before
holding a defendant liable for injuries caused to others. 9 Unfortunately,
we typically will be uncertain about the probability of bad outcomes
and the causal link between exposures and injuries. To prevent paralysis,
we must have some stopping rules enabling us to take action - such as
the marketing of a new drug or chemical - before all risks are "known"
and well characterized. If we adequately prioritize efforts to find the
greatest risks and concentrate our resources on discovering and
minimizing them, then the remaining risks should be reasonable. Given
the unavoidable but reduceable uncertainty and constrained resources,
what is the best way for society to manage risks?10
Our concern with the ability of the tort law to coherently manage
risks is that the signals are blurred by varying fact patterns between
cases, the workings of the trial courts are often obscured by lack of
publication and post-trial settlements, and decisions are post-hoc and
narrowly focused on injuries at hand.11 Benefits are downplayed, and
9 See, e.g., Restatement (Second) of Torts § 520 (1977) (abnormally dangerous
activities) and § 402A (abnormally dangerous condition of defective products). There
are a few courts, like Ferebee, that impose strict liability under a guise of failure to
warn of risks of which there was no reasonable obligation to discover. See Ayers v.
Johnson &Johnson Baby Products Co., 818 P.2d 1337 (Wash. 1991) (defendant
liable for brain damage caused by inhalation of baby oil). Courts holding that
foreseeability is not required ignore § 402A cmt. j, which requires a seller to give
warning of latent dangers "if he has knowledge, or by the application of reasonable,
developed human skill and foresight should have knowledge" of the risk.
10 See Richard Wilson, Edmund Crouch & Lauren Zeise, Uncertainty in Risk
Assessment (1985).
11 See also, Stephen Breyer, Breaking the Vicious Circle: Toward Effective Risk
Regulation (1993). At 59, Breyer, who is Chief Judge of the U.S. Court of Appeals for
the First Circuit, states:
Courts also administer a system of tort law which discourages
the negligent production of ris ly substances by forcing producers...
to compensate those whom they injure. That system, however,
leaves the determination of "too much risk" in the hands of tens of
thousands of different juries who are forced to answer the question
not in terms of a statistical life, but in reference to a very real victim
needing compensation in the courtroom before them. The result is a
system much criticized for its random, lotte.ry-like results and its
high "transactions costs .... Whatever its merits and problems, I do
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the context in which society trades off quality of life with acceptance of
some risks is hopelessly lost. The courts obviously have a role to play in
controlling risky technology, but the specific competencies and
limitations of administrative and judicial mechanisms need to be
balanced in determining what their respective roles should be.
Regulating Toxic Substances challenges the reader to think about
the potentially differing standards of evidence as used today in science,
regulatory science, policy making and civil litigation. It is also useful for
fleshing out the moral and legal issues involved in risk creation and
management. We found Cranor's analysis stimulating and well worth
reading.
Jon F. Merz & H. Christopher Freyt
not believe the tort system can serve as a substitute for government
regulation.
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